After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

Fampridine is the first medicine designed to improve walking in adults with MS and will now be routinely available on the NHS from today, NHS England has announced. Taken as a pill twice a day, ...

Thousands of people with multiple sclerosis (MS) in England will be offered a new drug on the NHS to help them walk more ...

With sales declining for aging multiple sclerosis (MS) drug Fampyra, Biogen has exercised an option to return licensing rights outside of the United States to Acorda Therapeutics. The move, which ...

The European Commission (EC) has granted a standard marketing authorization for FAMPYRA (prolonged-release fampridine tablets) for walking improvement in people with multiple sclerosis (MS), Biogen ...

Biogen Idec Canada announces that FAMPYRA - fampridine sustained release tablets or fampridine SR - is now available for prescription for patients living with multiple sclerosis, or MS, in Canada.

Biogen has a licensing deal with Acorda Therapeutics, Inc. (ACOR) for the development and commercialization of Fampyra in ex-US markets. Biogen is currently working on launching Fampyra in additional ...

The FINANCAL — The European Commission (EC) has granted a standard marketing authorization for FAMPYRA (prolonged-release fampridine tablets) for walking improvement in people with multiple sclerosis ...

Biogen’s Fampyra has been granted a standard approval by European regulators on the back of late-stage data supporting its use to improve walking in patients with multiple sclerosis. Biogen’s Fampyra ...

Gerard Murphy, 49, yesterday admitted he is still skeptical about the Government coughing up to provide potentially life-changing drug Fampyra to people with crippling MS Get daily headlines and ...